Advertisement
Advertisement
U.S. markets open in 2 hours 11 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Oncology Pharma Inc. (ONPH)

Other OTC - Other OTC Delayed Price. Currency in USD
0.4200+0.0200 (+5.00%)
At close: 03:56PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.4000
Open0.3950
BidN/A x N/A
AskN/A x N/A
Day's Range0.3800 - 0.4200
52 Week Range0.3200 - 7.2300
Volume88,539
Avg. Volume65,392
Market Cap794,514
Beta (5Y Monthly)0.13
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ONPH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ONCOLOGY PHARMA INC
    Analyst Report: Qiagen N.V.Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (45% of 2021 sales), followed by EMEA (36%) and Asia-Pacific (19%).
    Rating
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
Advertisement
Advertisement